12/15
08:27 pm
prax
Has Praxis Precision Medicines Rally Gone Too Far or Is the Market Still Missing Something [Yahoo! Finance]
Medium
Report
Has Praxis Precision Medicines Rally Gone Too Far or Is the Market Still Missing Something [Yahoo! Finance]
12/15
10:04 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) was given a new $750.00 price target on by analysts at UBS Group AG.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) was given a new $750.00 price target on by analysts at UBS Group AG.
12/15
07:21 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
12/12
11:03 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) was given a new $313.00 price target on by analysts at Deutsche Bank Aktiengesellschaft.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) was given a new $313.00 price target on by analysts at Deutsche Bank Aktiengesellschaft.
12/12
08:33 am
prax
Praxis Precision to file an NDA for relutrigine in encephalopathies in 2026 [Yahoo! Finance]
Low
Report
Praxis Precision to file an NDA for relutrigine in encephalopathies in 2026 [Yahoo! Finance]
12/11
08:27 am
prax
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 [Yahoo! Finance]
Low
Report
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 [Yahoo! Finance]
12/11
08:00 am
prax
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
Low
Report
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
12/9
04:01 pm
prax
Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
Low
Report
Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
12/9
12:17 pm
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/9
07:21 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Guggenheim.
Medium
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/9
12:27 am
prax
Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins [Yahoo! Finance]
Low
Report
Praxis Precision Medicines Inc. (PRAX) Secures Analyst Confidence After Key FDA and Trial Wins [Yahoo! Finance]
12/8
11:41 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at TD Cowen from $251.00 to $353.00. They now have a "buy" rating on the stock.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at TD Cowen from $251.00 to $353.00. They now have a "buy" rating on the stock.
12/8
10:47 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Truist Financial Corporation from $360.00 to $500.00. They now have a "buy" rating on the stock.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Truist Financial Corporation from $360.00 to $500.00. They now have a "buy" rating on the stock.
12/8
10:13 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/8
09:13 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) was given a new $507.00 price target on by analysts at BTIG Research.
Medium
Report
Praxis Precision Medicines (NASDAQ:PRAX) was given a new $507.00 price target on by analysts at BTIG Research.
12/8
08:07 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Needham & Company LLC from $304.00 to $315.00. They now have a "buy" rating on the stock.
Medium
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Needham & Company LLC from $304.00 to $315.00. They now have a "buy" rating on the stock.
12/8
08:00 am
prax
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
Medium
Report
Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
12/6
06:30 am
prax
Praxis Precision Medicines (PRAX): Reassessing Valuation After EMBOLD Success and Ulixacaltamide Pre-NDA Milestone [Yahoo! Finance]
Medium
Report
Praxis Precision Medicines (PRAX): Reassessing Valuation After EMBOLD Success and Ulixacaltamide Pre-NDA Milestone [Yahoo! Finance]
12/5
03:16 pm
prax
How EMBOLD Efficacy Stop And Ulixacaltamide FDA Pathway At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story [Yahoo! Finance]
Low
Report
How EMBOLD Efficacy Stop And Ulixacaltamide FDA Pathway At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story [Yahoo! Finance]
12/5
02:47 pm
prax
Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 [Seeking Alpha]
Low
Report
Praxis Precision Medicines: Latest Study Wins Sets Up 2 CNS Drug Approvals In 2026 [Seeking Alpha]
12/5
01:27 pm
prax
Top Midday Gainers [Yahoo! Finance]
Low
Report
Top Midday Gainers [Yahoo! Finance]
12/5
12:13 pm
prax
Praxis Precision Medicines (NASDAQ:PRAX) was given a new $304.00 price target on by analysts at Needham & Company LLC.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) was given a new $304.00 price target on by analysts at Needham & Company LLC.
12/5
10:59 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/5
09:11 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
12/5
08:44 am
prax
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at BTIG Research.
Low
Report
Praxis Precision Medicines (NASDAQ:PRAX) had its "buy" rating reaffirmed by analysts at BTIG Research.